Shots:
- Endevica Bio conducting P-II study in collaboration with WuXi Clinical reported the dose administration of B07 in first patient to prevent weight loss in cancer patients diagnosed with stage 4 metastatic colorectal cancer undergoing CT
- In 2024, Endevica Bio completed its P-I study, with early results showing strong safety and efficacy. In current P-II study the 1EP is preventing weight loss and patients will be dosed with B07 while starting CT and during the first several rounds of CT
- B07 is a melanocortin-3/4 receptor antagonist peptide that can cross blood-brain barrier and modulate behavioral & metabolic responses to chronic illness
Ref: Prnewswire | Image: Endevica Bio
Related News:- Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
